DXCM Stock Recent News
DXCM LATEST HEADLINES
DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results. Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch as a primary display for blood sugars. Despite concerns over timing and other risks, I believe there will be sustained revenue growth and that there is potential for long-term price accretion.
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom, Inc. (NASDAQ:DXCM ) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Danielle Antalffy - UBS Securities Robbie Marcus - J.P. Morgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citibank Jeff Johnson - Robert W.
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth.